Calprotectin and CRP as biomarkers of cardiovascular disease risk in patients with chronic kidney disease: a follow-up study at 5 and 10 years

References

• Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–352.
   PubMed Web of Science ®Google Scholar
• Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–2081.
   PubMed Web of Science ®Google Scholar
• Cachofeiro V, Goicochea M, de Vinuesa SG, et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl. 2008;74:S4–S9.
   Web of Science ®Google Scholar
• Weiner DE, Tighiouart H, Elsayed EF, et al. Inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney Int. 2008;73(12):1406–1412.
   PubMed Web of Science ®Google Scholar
• Amdur RL, Feldman HI, Dominic EA, et al. Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study. Am J Kidney Dis. 2019;73(3):344–353.
   PubMed Web of Science ®Google Scholar
• Sela S, Shurtz-Swirski R, Cohen-Mazor M, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16(8):2431–2438.
   PubMed Web of Science ®Google Scholar
• Silvestre-Roig C, Braster Q, Ortega-Gomez A, et al. Neutrophils as regulators of cardiovascular inflammation. Nat Rev Cardiol. 2020;17(6):327–340.
   PubMed Web of Science ®Google Scholar
• Vogl T, Gharibyan AL, Morozova-Roche LA. Pro-inflammatory S100A8 and S100A9 proteins: self-assembly into multifunctional native and amyloid complexes. Int J Mol Sci. 2012;13(3):2893–2917.
   PubMed Web of Science ®Google Scholar
• Voganatsi A, Panyutich A, Miyasaki KT, et al. Mechanism of extracellular release of human neutrophil calprotectin complex. J Leukoc Biol. 2001;70(1):130–134.
   PubMed Web of Science ®Google Scholar
• Tardif MR, Chapeton-Montes JA, Posvandzic A, et al. Secretion of S100A8, S100A9, and S100A12 by neutrophils involves reactive oxygen species and potassium efflux. J Immunol Res. 2015;2015:296149.
   PubMed Web of Science ®Google Scholar
• Viemann D, Strey A, Janning A, et al. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood. 2005;105(7):2955–2962.
   PubMed Web of Science ®Google Scholar
• Pruenster M, Kurz AR, Chung KJ, et al. Extracellular MRP8/14 is a regulator of beta2 integrin-dependent neutrophil slow rolling and adhesion. Nat Commun. 2015;6:6915.
   PubMed Web of Science ®Google Scholar
• Ehrchen JM, Sunderkotter C, Foell D, et al. The endogenous toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86(3):557–566.
   PubMed Web of Science ®Google Scholar
• Pruenster M, Vogl T, Roth J, et al. S100A8/A9: from basic science to clinical application. Pharmacol Ther. 2016;167:120–131.
   PubMed Web of Science ®Google Scholar
• Healy AM, Pickard MD, Pradhan AD, et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation. 2006;113(19):2278–2284.
   PubMed Web of Science ®Google Scholar
• Cotoi OS, Duner P, Ko N, et al. Plasma S100A8/A9 correlates with blood neutrophil counts, traditional risk factors, and cardiovascular disease in middle-aged healthy individuals. Arterioscler Thromb Vasc Biol. 2014;34(1):202–210.
   PubMed Web of Science ®Google Scholar
• Kunutsor SK, Flores-Guerrero JL, Kieneker LM, et al. Plasma calprotectin and risk of cardiovascular disease: findings from the PREVEND prospective cohort study. Atherosclerosis. 2018;275:205–213.
   PubMed Web of Science ®Google Scholar
• Averill MM, Kerkhoff C, Bornfeldt KE. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol. 2012;32(2):223–229.
   PubMed Web of Science ®Google Scholar
• Croce K. S100A8/A9 complex: more than just a biomarker of cardiovascular risk? Circ J. 2010;74(4):626–627.
   PubMed Web of Science ®Google Scholar
• Hov GG, Sagen E, Hatlen G, et al. Arginine/asymmetric dimethylarginine ratio and cardiovascular risk factors in patients with predialytic chronic kidney disease. Clin Biochem. 2011;44(8–9):642–646.
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–254.
   PubMed Web of Science ®Google Scholar
• Ladhani M, Craig JC, Irving M, et al. Obesity and the risk of cardiovascular and all-cause mortality in chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2017;32:439–449.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Wang Y, Croce K, et al. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the pravastatin or atorvastatin evaluation and infection therapy: thrombolysis in myocardial infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008;155(1):49–55.
   PubMed Web of Science ®Google Scholar
• Ortega FJ, Sabater M, Moreno-Navarrete JM, et al. Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. Eur J Endocrinol. 2012;167(4):569–578.
   PubMed Web of Science ®Google Scholar
• Pedersen L, Nybo M, Poulsen MK, et al. Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients. BMC Cardiovasc Disord. 2014;14:196.
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1):85–97.
   PubMed Web of Science ®Google Scholar
• Schiopu A, Cotoi OS. S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease. Mediators Inflamm. 2013;2013:828354.
   PubMed Web of Science ®Google Scholar
• Viemann D, Barczyk K, Vogl T, et al. MRP8/MRP14 impairs endothelial integrity and induces a caspase-dependent and -independent cell death program. Blood. 2007;109(6):2453–2460.
   PubMed Web of Science ®Google Scholar
• Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165(6):710–718.
   PubMed Web of Science ®Google Scholar
• Diamantis E, Kyriakos G, Quiles-Sanchez LV, et al. The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature. Curr Cardiol Rev. 2017;13:209–216.
   PubMed Web of Science ®Google Scholar
• Åsberg A, Løfblad L, Felic A, et al. Measuring calprotectin in plasma and blood with a fully automated turbidimetric assay. Scand J Clin Lab Invest. 2019;79(1–2):50–57.
   PubMed Web of Science ®Google Scholar
• Mylemans M, Nevejan L, Van Den Bremt S, et al. Circulating calprotectin as biomarker in neutrophil-related inflammation: pre-analytical recommendations and reference values according to sample type. Clin Chim Acta. 2021;517:149–155.
   PubMed Web of Science ®Google Scholar